The biobanking market is expected to reach a size of ~$71.2 billion by 2026, registering a compound annual growth rate (CAGR) of ~5.2% from 2020.
The biobanking ecosystem is witnessing significant transformation. Emergence of one-stop shops and virtual biobanks, rise in services offered to sustain and improve positioning, and precision medicine are characterizing this transformative environment. While Europe is the highest contributor to the total market, Asia-Pacific (APAC) is expected to witness the highest growth during the forecast period (2020 to 2026) of this research.
This market will be driven further by innovation in targeted therapeutic applications, high sample utilization of tissue/stem cells, and the increasing demand for bio-data for enabling patient stratification. Significant growth opportunities for biobanks are in the areas of companion diagnostics (CDx) co-development, large-scale genome sequencing projects, immuno-oncology clinical development, digital pathology services, and real-world evidence (RWE) studies.
The shifting industry paradigm towards commercial partnerships with pharmaceutical and biotech companies, contract research organizations (CROs), and contract development and manufacturing organizations (CDMOs), as well as diagnostics and digital solution providers is expected to further boost market growth. Biobanks are partnering with end-users for customized research-based engagements as niche providers of samples and services and as data owners. However, they need to better understand the changing end-user needs and transition to innovative value-based data pricing and hybrid models for ensuring operational sustainability in the future.
Collaborations with commercial partners by fulfilling key selection criteria and engaging with well-defined models are a critical requirement for biobanks to retain market share. A number of leading biobanks in the United States, the United Kingdom, Sweden, and Denmark have taken major strides in adopting and implementing industry best practices in the last few years.
Key Topics Covered:
1. Strategic Imperatives
Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8
The Impact of the Top Five Strategic Imperatives on the Biobanking Industry
Growth Opportunities Fuel the Growth Pipeline Engine
2. Growth Opportunity Analysis, Biobanking Market
Biobanking Market, Scope of Analysis
Biobanking Market, Scope of Analysis - COVID-19 Impact
Biobanking Market, Scope of Analysis - Key Market Themes
Biobanking Market, Scope of Analysis - Value Chain & Key Stakeholders
Biobanking Market, Scope of Analysis - Workflow Optimization
Biobanking Market, Scope of Analysis - Future Role of Biobanks
Biobanking Market, Segmentation
Key Competitors and End-users in the Biobanking Market
Key Growth Metrics for the Biobanking Market
Growth Drivers for the Biobanking Market
Growth Driver Analysis for the Biobanking Market
Growth Restraints for the Biobanking Market
Growth Restraint Analysis for the Biobanking Market
Prothena Corporation plc , a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2024 and provided...
Myomo, Inc. ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended...
QuidelOrtho Corporation (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the first...
Acadia Pharmaceuticals Inc. today announced its financial results for the first quarter ended March 31, 2024.
"In the first quarter of 2024, Acadia delivered net product sales of $205.8 million, representing 74% revenue growth year over year,...
Zai Lab Limited today announced financial results for the first quarter of 2024, along with recent product highlights and corporate updates.
"Our first quarter results demonstrate strong commercial execution and pipeline progress across our...
ChromaDex Corp. today announced financial results for the first quarter of 2024.
First Quarter 2024 Financial and Recent Operational Highlights
Total net sales were $22.2 million, with $17.4 million from Tru Niagen®.
Solid gross margin of...